Cellular immune responses against the cancer-testis antigen SPAN-XB in healthy donors and patients with multiple myeloma

• Verfasst von: Frank, Christian [VerfasserIn]
• Verfasst von: Hundemer, Michael [VerfasserIn]
• Verfasst von: Ho, Anthony Dick [VerfasserIn]
• Verfasst von: Goldschmidt, Hartmut [VerfasserIn]
• Verfasst von: Witzens-Harig, Mathias [VerfasserIn]
• Titel: Cellular immune responses against the cancer-testis antigen SPAN-XB in healthy donors and patients with multiple myeloma
• Verf.angabe: Christian Frank, Michael Hundemer, Anthony D. Ho, Hartmut Goldschmidt, Mathias Witzens-Harig
• Jahr: 2008
• Umfang: 7 S.
• Fussnoten: Published online: 01 Jul 2009 ; Gesehen am 12.10.2021
• Titel Quelle: Enthalten in: Leukemia and lymphoma
• Ort Quelle: London [u.a.] : Taylor & Francis Group, 1989
• Jahr Quelle: 2008
• Band/Heft Quelle: 49(2008), 4, Seite 779-785
• ISSN Quelle: 1029-2403
• DOI: doi:10.1080/10428190801911688
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: immunobiology
• Sach-SW: immunotherapy
• Sach-SW: myeloma
• Sach-SW: neoplasia
• Sach-SW: T-cell mediated immunity
• K10plus-PPN: 1773395238

Abstract

The cancer-testis antigen SPAN-XB has been recently identified in multiple myeloma (MM). In the present study, we identified and characterized for the first time a cytotoxic cellular immune response against SPAN-XB in healthy donors and patients with MM. Using two independent computer algorithms, two SPAN-XB-derived peptides (peptides 624 and 626) with predicted binding to HLA-A2 were identified. To further improve the immunogenicity of peptide 626 we designed a heteroclitic peptide (peptide 627) by modifying one amino acid on the HLA binding position 2 of peptide 626. Using an IFN-γ Elispot assay we could demonstrate the presence and functional activity of CD8 peptide specific T cells with all tested peptides. By analysis of peripheral blood of 13 healthy donors and five patients with MM peptide specific T-cell precursors specifically recognizing at least one of the tested peptides could be detected and expanded in 9 of 13 of tested donors and 3 of 5 tested patients. Importantly, in two donors specific peptides could be generated against the heteroclitic peptide 627 but not against the native peptide 626. We conclude that SPAN-XB-derived peptides can elicit a consistent CD8 T cell response in healthy donors and patients with MM.